EasyM is a highly sensitive mass spectrometry-based blood test for monitoring minimal residual disease (MRD) in multiple myeloma. EasyM is available for clinical use in both the United States (CLIA-approved) and Canada (provisional MOH licence). Clinical studies demonstrate high concordance with NGS-based MRD assays, predictive value for disease progression, and greater sensitivity than conventional methods.